The deal combines ACR’s clinical research capacity with GPSI’s consultation, training and auditing services in a partnership that, they hope, will attract new customers in India and the US.
Russell told Outsoucing-pharma that part of the motivation for setting up the partnership was GPSI’s recognition of the need to build clinical R&D capacity that is attractive to potential sponsors.
“Through its’ business activities with US pharma and biotech companies, GPSI had become apprised of the need for the placement of clinical studies in facilities that were conducting clinical studies efficiently and on time, at a reasonable cost and, most importantly, uncompromisingly meeting regulatory guidelines.”
“Dr. Emran Khan, Director of Abridge Clinical Research, was introduced to GPSI by a mutual business colleague. Following several information exchanges including in-depth discussions regarding business philosophies, opportunities for collaboration were identified.”
Russell explained that ACR will serve as project manager for all US trial sponsors, identifying the most appropriate service provider based on its knowledge of Indian contract research organizations (CRO).
He added that “Abridge Clinical Research will negotiate the contract directly with the service provider based upon a working proposal generated by the client or by Abridge Clinical Research.
“Contract negotiations will be done by an Abridge Clinical Research representative, in the local language who is knowledgeable of the business environment in India, which will mean a lower overall cost to the client.”
GPSI will act as US project manager for all studies conducted in India, providing clients with a point of contact that will, according to Russell, “eliminate the typical communication difficulties encountered when dealing on an international basis.”